Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » General » History of Carcinoid Tumour diagnosis

History of Carcinoid Tumour diagnosis

  • April 25, 2018

At a recent NET support group
meeting a question was asked about when NETs were first diagnosed? Upon
researching this question it has been reported that the histology (which is
defined as the study of the form of structures seen under the microscope) was first
seen by Theodor Langhans. Langhans was the first to describe the histology of
the carcinoid tumour in 1868; however Otto Lubarsch has been credited with the
first report of two patients with ileal carcinoid tumours which were discovered
at autopsy in 1888. A German pathologist Siegfried Obendorfer at the University
of Munich, in 1907 created the term “karzinoide” or “carcinoma-like” because their slow growth was considered to be
"cancer-like" rather than truly cancerous
, however under the
microscope it did resemble carcinoma. Recognition of the endocrine-related
properties of carcinoid tumours did not happen till much later. Rapport and
colleagues in 1948 isolated and named serotonin which was initially identified
as a vasoconstrictor substance in the serum. Enterochromaffin cells, which give rise to carcinoid tumors, were
identified in 1897 by Nikolai Kulchitsky
and their
secretion
of serotonin was established
in 1953 when the "flushing" effect of serotonin had become clinically
recognized by Lembeck and confirmed it as the major hormone responsible for
carcinoid syndrome. Carcinoid heart disease was identified in 1952, and
carcinoid fibrosis in 1961
.

NET tumours were initially
assessed as carcinoid and these tumours still raise many issues regarding
classification, prognosis and choice of the best therapeutic approach. The
incidence and prevalence of NET seems to have increased in recent years, most
likely due to an improvement in diagnostic techniques, continued research and
clinician awareness.

Share this post

Recent posts

VHL Awareness Month 2025

May 6, 2025

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

May 5, 2025

Help Us Grow: Connect NECA with Corporate Partners to Make a Lasting Impact

April 29, 2025

Neuroendocrine Cancer Awareness Daily Mail 5 April 2025

April 5, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousAPNETs is coming to Melbourne
NextUnicorn Foundation exhibits at 12th Congress WFNMBNext

Related Posts

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

NeuroEndocrine Cancer Australia (NECA) is proud to recognise the advocacy efforts of NET patient Chris Geljon, who has taken the time to raise awareness of

NECA Christmas and New Year Closure Details

Neuroendocrine Cancer Australia advises holiday closure dates from Tuesday 24 December 2024 to Friday 3 January 2025. We will reopen on Monday 6 January 2025.

Sydney Unicorn Get Together 2024

On the eve of Neuroendocrine Cancer Day, we were thrilled to join in this special patient-organised event, celebrating a record turnout of nearly 50 patients,

Team Janine completes City2Surf and raises over $9,000 for NECA

Team Janine walked arm in arm in memory of NET Patient Janine during City2Surf this weekend. Many thanks to Melinda, Sally, Margie, Julie, Kate, Georgia,

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin